The DOI matches its Crossref record.
Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy
Open accessAbstract
Background Monoclonal antibodies directed at IgE demonstrate clinical efficacy in subjects with peanut allergy, but previous studies have not addressed the kinetics of the clinical response or the role of mast cells and basophils in the food-induced allergic response. Objective We sought to determine the kinetics of the clinical response to omalizumab and whether clinical improvement is associated with either mast cell or basophil suppression. Methods Subjects with peanut allergy were treated with omalizumab for 6 months and assessed for clinical and cellular responses. At baseline, subjects had a double-blind, placebo-controlled oral food challenge (OFC), skin prick test titration (SPTT), and basophil histamine release (BHR) to peanut. BHR was repeated at week 2 and then weekly until it decreased to less than 20% of baseline values. The OFCs and SPTTs were repeated after the BHR reduction (or at week 8 if BHR did not decrease) and again at 6 months. Results Fourteen subjects enrolled in the study. At the second food challenge, there was a significant increase in the threshold dose of peanut inducing allergic symptoms (80 to 6500 mg, P < .01). Peanut-induced BHR was either completely suppressed (n = 5) or 10-fold more allergen was required to induce maximal BHR (n = 9), and SPTT responses were not significantly changed from baseline. After 6 months of omalizumab, further changes in the OFC threshold dose or BHR were not observed, but a significant suppression in SPTTs was identified. Conclusions The clinical response to omalizumab occurs early in treatment when the basophil, but not the mast cell, is suppressed, supporting a role for the basophil in acute food reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease
Hoffmann, H. J., Santos, A. F., Mayorga, C., Nopp, A., Eberlein, B., Ferrer, M., Rouzaire, P., Ebo, D. G., Sabato, V., Sanz, M. L., et al. (2015) · Allergy · doi:10.1111/all.12698 · Cited by 403
Tordesillas, L., Berin, M. C., & Sampson, H. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.004 · Cited by 337
Basophils and allergic inflammation
Siracusa, M. C., Kim, B. S., Spergel, J. M., & Artis, D. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.046 · Cited by 313
EAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, A. P., Giménez-Arnau, A. M., & Saini, S. S. (2017) · Allergy · doi:10.1111/all.13083 · Cited by 293
Self-citation
Metadata
- Authors
- Savage, J. H., Courneya, J.-P., Sterba, P. M., MacGlashan, D. W., Saini, S. S., & Wood, R. A.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 130
- Issue
- 5
- Pages
- 1123-1129.e2
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1971723752
- Cited by
- 190
- References
- 0
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. https://app.cochat.ai/papers/10.1016/j.jaci.2012.05.039
- The paper
- Savage, J. H., Courneya, J.-P., Sterba, P. M., MacGlashan, D. W., Saini, S. S., & Wood, R. A. (2012). Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2012.05.039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.